Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

ElexoPharm GmbH - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 24 | Code: MRS - 7046


Global Markets Direct’s, ‘ElexoPharm GmbH Product Pipeline Review 2015’, provides an overview of the ElexoPharm GmbH’s pharmaceutical research and development focus.


This report provides comprehensive information on the current therapeutic developmental pipeline of ElexoPharm GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.




The report provides brief overview of ElexoPharm GmbH including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of ElexoPharm GmbH’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the ElexoPharm GmbH’s pipeline products


Reasons to buy


Evaluate ElexoPharm GmbH’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of ElexoPharm GmbH in its therapy areas of focus
Identify new drug targets and therapeutic classes in the ElexoPharm GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of ElexoPharm GmbH and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of ElexoPharm GmbH
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of ElexoPharm GmbH and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents


Table of Contents 2
List of Tables 3
List of Figures 3
ElexoPharm GmbH Snapshot 4
ElexoPharm GmbH Overview 4
Key Information 4
Key Facts 4
ElexoPharm GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
ElexoPharm GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
ElexoPharm GmbH - Pipeline Products Glance 13
ElexoPharm GmbH - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
ElexoPharm GmbH - Drug Profiles 15
Small Molecule to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Eurostars Program 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ElexoPharm GmbH - Pipeline Analysis 19
ElexoPharm GmbH - Pipeline Products by Target 19
ElexoPharm GmbH - Pipeline Products by Molecule Type 20
ElexoPharm GmbH - Pipeline Products by Mechanism of Action 21
ElexoPharm GmbH - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22


Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 23
Disclaimer 24


List of Tables

ElexoPharm GmbH, Key Information 4
ElexoPharm GmbH, Key Facts 4
ElexoPharm GmbH - Pipeline by Indication, 2015 6
ElexoPharm GmbH - Pipeline by Stage of Development, 2015 7
ElexoPharm GmbH - Monotherapy Products in Pipeline, 2015 8
ElexoPharm GmbH - Partnered Products in Pipeline, 2015 9
ElexoPharm GmbH - Partnered Products/ Combination Treatment Modalities, 2015 10
ElexoPharm GmbH - Out-Licensed Products in Pipeline, 2015 11
ElexoPharm GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
ElexoPharm GmbH - Preclinical, 2015 13
ElexoPharm GmbH - Discovery, 2015 14
ElexoPharm GmbH - Pipeline by Target, 2015 19
ElexoPharm GmbH - Pipeline by Molecule Type, 2015 20
ElexoPharm GmbH - Pipeline Products by Mechanism of Action, 2015 21
ElexoPharm GmbH, Other Locations 22"


List of Figures

ElexoPharm GmbH - Pipeline by Top 10 Indication, 2015 6
ElexoPharm GmbH - Pipeline by Stage of Development, 2015 7
ElexoPharm GmbH - Monotherapy Products in Pipeline, 2015 8
ElexoPharm GmbH - Pipeline by Top 10 Target, 2015 19
ElexoPharm GmbH - Pipeline by Top 10 Molecule Type, 2015 20
ElexoPharm GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015 21

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing